Revascularization between 48 hours and 7 days after initial stroke is supported by these data in cases of nondisabling stroke (mRS score 0 2).334 See Table LXXVIII in online Data Supplement 1. 6.8. Treatment of Hyperlipidemia 6.8.1. General Principles COR LOE New, Revised, or Unchanged Patients with AIS should be managed according to the 2018 ACC/AHA Cholesterol Guidelines, which include lifestyle modification, dietary recommendations, and medication recommendations. I A Recommendation, COR, and LOE updated from 2014 Secondary Prevention to reference 2018 Cholesterol Guidelines The 2018 Cholesterol Guidelines provide a comprehensive set of recommendations for managing hyperlipidemia.19 Those recommendations that are most pertinent to the in-hospital management of patients with AIS are excerpted here. The full guidelines should be used for guidance in managing these disorders in patients with AIS and for supporting evidence. In adults who are 20 years of age or older and not on lipid-lowering therapy, measurement of either a fasting or a nonfasting plasma lipid profile is effective in estimating atherosclerotic cardiovascular disease (ASCVD) risk and documenting baseline low-density lipoprotein cholesterol (LDL-C). I B-NR Recommendation unchanged from 2018 Cholesterol Guidelines. Adherence to changes in lifestyle and effects of LDL-C lowering medication should be assessed by measurement of fasting lipids and appropriate safety indicators 4 to 12 weeks after statin initiation or dose adjustment and every 3 to 12 months thereafter based on need to assess adherence or safety. I A Recommendation unchanged from 2018 Cholesterol Guidelines. 6.8.2. Choice of Lipid-lowering Drugs for Patients with Clinical ASCVD* COR LOE New, Revised, or Unchanged In patients who are 75 years of age or younger with clinical ASCVD, high- intensity statin therapy should be initiated or continued with the aim of achieving a 50% or greater reduction in LDL-C levels. I A Recommendation unchanged from 2018 Cholesterol Guidelines. 